hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06268262, orgStudyIdInfo id: XYFY2023-KL045-01, briefTitle: Surgical-imaging Research on Obesity (SIRO), statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: The Affiliated Hospital of Xuzhou Medical University, class: OTHER, descriptionModule briefSummary: The global obesity epidemic is well established, and is an important public health issue. The previous researches had applied the clues that obesity is a kind of systemic disease. The investigators hypothesized that a serious alteration of the body systems will occur after bariatric surgery, which may shed light on the mechanisms of obesity. Thus, the research aims to combine the imaging and surgery to investigate the alterations of the body that induced by obese and alterations after surgery., conditionsModule conditions: Overweight and Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Imaging parameters of obesity, primaryOutcomes measure: Imaging parameters of obesity, primaryOutcomes measure: Imaging parameters of obesity, secondaryOutcomes measure: Neurotransmitter, inflammatory factors and hormones related to obesity in blood sample, secondaryOutcomes measure: Neurotransmitter, inflammatory factors and hormones relating to obesity in blood sample, secondaryOutcomes measure: Neurotransmitter, inflammatory factors and hormones related to obesity in blood sample, secondaryOutcomes measure: Genetic information from venous blood sample, biopsied liver tissue, biopsied fat tissue, and gastric tissue, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Affiliated Hospital of Xuzhou Medical University, status: RECRUITING, city: Xuzhou, state: Jiangsu, zip: 221000, country: China, contacts name: Kai Liu, M.D/Ph.D, role: CONTACT, phone: +86-15920157720, email: liu-k@hotmail.com, geoPoint lat: 34.18045, lon: 117.15707, hasResults: False
protocolSection identificationModule nctId: NCT06268249, orgStudyIdInfo id: TJ-IRB20231224, briefTitle: Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-01-01, primaryCompletionDateStruct date: 2022-12-30, completionDateStruct date: 2023-12-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Qin Zhang, class: OTHER, descriptionModule briefSummary: This study is a retrospective, observational study that aims to include patients undergoing cardiac surgery. 1. Evaluate the preventive effect of ursodeoxycholic acid on post-cardiac surgery cognitive dysfunction over the past eight years. 2. Utilize the pre-existing preoperative and postoperative 24-hour plasma samples from previous studies to measure the levels of glycocalyx and its related regulatory factors. 3. Assess the clinical correlation between the measured parameters and patient outcomes., conditionsModule conditions: Cardiac Complication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 7065, type: ACTUAL, armsInterventionsModule interventions name: Ulinastatin, outcomesModule primaryOutcomes measure: POCD - Postoperative Cognitive Dysfunction, secondaryOutcomes measure: Survival time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430030, country: China, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06268236, orgStudyIdInfo id: BF2023-252, briefTitle: Electro-acupuncture to Treat Disorder of Consciousness, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2026-01-31, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, class: OTHER, descriptionModule briefSummary: With the rapid development of life support technology, more and more people can survive severe brain injury. Some survivors regain consciousness after a period of coma, however, many patients develop prolonged disorders of consciousness (DOC), which poses a therapeutic challenge for clinicians and a heavy burden for their families. The investigators design an Electro-acupuncture to treat disorder of consciousness (AcuDoc) trial with the aim of validating the clinical effect of electroacupuncture in treating DOC and exploring its therapeutic mechanisms by integrating EEG, neuroimaging, evoked potential tests, and behavioral assessments., conditionsModule conditions: Disorder of Consciousness, conditions: Electroacupuncture, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Electroacupuncture, interventions name: Sham electroacupuncture, outcomesModule primaryOutcomes measure: Coma Recovery Scale - Revised score, secondaryOutcomes measure: phase locking value, secondaryOutcomes measure: amplitude of low-frequency fluctuation, secondaryOutcomes measure: Amide proton transfer-weighted signal, secondaryOutcomes measure: f value, secondaryOutcomes measure: neurite density index, secondaryOutcomes measure: latency value of N20, secondaryOutcomes measure: latency between III and V potentials, secondaryOutcomes measure: Glasgow Outcome Scale-Extended score, secondaryOutcomes measure: Glasgow Outcome Scale-Extended score, secondaryOutcomes measure: brain-computer interface accuracy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510120, country: China, contacts name: Fang Yuan, PhD, role: CONTACT, phone: +86-20-81887233, email: plawlx@gzucm.edu.cn, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06268210, orgStudyIdInfo id: 4-2023-1546, briefTitle: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer, acronym: NeoLazer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2028-06, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Yonsei University, class: OTHER, descriptionModule briefSummary: In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy as neoadjuvant therapy in patients with resectable, treatment-naive EGFR-mutant (exon 19 deletion or exon 21 L858R) non-small cell lung cancer, ranging from clinical stage IB to IIIB. The study is designed to assess the impact on pathological response, as well as effectiveness and safety considerations., conditionsModule conditions: Non-small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: Lazertinib+Pemetrexed+Carboplatin, interventions name: Lazertinib, outcomesModule primaryOutcomes measure: Primary pathological response, secondaryOutcomes measure: Surgical Resection Methods (Segmentectomy or Lobectomy), secondaryOutcomes measure: Pathologic Complete Response, secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Event-Free Survival, secondaryOutcomes measure: Disease-Free Survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Number of patients with Adverse events according to CTCAE v5.0, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Severance hospital, city: Seoul, country: Korea, Republic of, contacts name: Hye Ryun Kim, role: CONTACT, phone: 82-2-2228-8125, email: nobelg@yuhs.ac, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06268197, orgStudyIdInfo id: IRB23-0329, briefTitle: Interoception-Based Yoga for Chronic Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: University of Illinois at Urbana-Champaign, class: OTHER, descriptionModule briefSummary: The purpose of this research is to examine the feasibility and acceptability of an interoception-based yoga program for chronic pain. Interoception involves your ability to feel sensations in your body (such as your heartbeat or muscle tension) as well as how you think about and interpret those sensations. Interoception may be an important component of chronic pain and the research team is studying whether yoga can change how you feel, think about, and interpret sensations in your body., conditionsModule conditions: Chronic Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Yoga Intervention, outcomesModule primaryOutcomes measure: Feasibility, primaryOutcomes measure: Acceptability, secondaryOutcomes measure: Interoceptive Sensibility, secondaryOutcomes measure: PROMIS Pain Interference, otherOutcomes measure: Interoceptive Accuracy, otherOutcomes measure: Mindfulness, otherOutcomes measure: PROMIS Pain Intensity, otherOutcomes measure: Quality of Life, otherOutcomes measure: Spiritual Wellbeing, otherOutcomes measure: Pain Impact, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Illinois Urbana-Champaign, status: RECRUITING, city: Urbana, state: Illinois, zip: 61801, country: United States, contacts name: Project Coordinator, role: CONTACT, phone: 217-265-0741, email: svoss2@illinois.edu, contacts name: Neha P Gothe, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Steven Petruzzello, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 40.11059, lon: -88.20727, hasResults: False
protocolSection identificationModule nctId: NCT06268184, orgStudyIdInfo id: omega3 in oxidative stress, briefTitle: Effect of Omega 3 on Oxidative Stress and Nutritional Status of Children on Regular Dialysis, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-10-04, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: evaluaion the effects of oral omega-3 supplementation on nutritional status and oxidative stress in pediatric patients with end stage renal disease on regular hemodialysis, conditionsModule conditions: Oxidative Stress, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: group 1: 30 children with ESRD receive omega 3 supplementation group 2:15 children with ESRD receive lpacebo, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: D3 LAB SYRUP, interventions name: placebo capsule, outcomesModule primaryOutcomes measure: decrease oxidative stress, primaryOutcomes measure: increase antioxidant activity, primaryOutcomes measure: improvement of nutritional status assessed by anthropometric measurements., primaryOutcomes measure: mid upper arm circumference in centimeters, primaryOutcomes measure: triceps skin fold thickness in millimeter's, primaryOutcomes measure: improvement of nutritional status assessed by Bioelectrical Inbody Analysis(BIA), primaryOutcomes measure: improvement of nutritional status assessed by Bioelectrical Inbody Analysis(BIA), primaryOutcomes measure: improvement of nutritional status assessed by Bioelectrical Inbody Analysis(BIA), primaryOutcomes measure: improvement of nutritional status assessed by Bioelectrical Inbody Analysis(BIA), primaryOutcomes measure: improvement of nutritional status assessed by Bioelectrical Inbody Analysis(BIA), primaryOutcomes measure: improvement of nutritional status assessed by laboratory investigations., primaryOutcomes measure: s. ionized calcium level, primaryOutcomes measure: s.phosphorus level, primaryOutcomes measure: alkaline phosphatase level, primaryOutcomes measure: parathormone hormone level, primaryOutcomes measure: 25(oh)vitamin D level, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Medicine, status: RECRUITING, city: Tanta, state: Gharbia, country: Egypt, contacts name: Noha sayed ahmed, M.Sc, role: CONTACT, phone: 01016919217, phoneExt: 01097722167, email: noooooha1990@gmail.com, contacts name: rasha gamal elshafaay, MD, role: CONTACT, phone: 01227405988, phoneExt: 01114277784, email: rashagamal1978@gmail.com, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06268171, orgStudyIdInfo id: 2023_0214, secondaryIdInfos id: 2023-A02390-45, type: OTHER, domain: ANSM, briefTitle: Ultrasound Assessment of Rectus Femoris Cross-sectionnal Area Following Lung Transplantation, acronym: EchoSS-TP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2025-09-04, completionDateStruct date: 2025-11-05, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Hopital Foch, class: OTHER, descriptionModule briefSummary: In France, the profile of patients receiving lung transplants has changed in recent years, mainly due to the advent of treatment for cystic fibrosis. This progress has led to an evolution in the patient profile, with an increase in cases of pulmonary fibrosis or COPD, and an increase in the average age of patients. In these older patients, sarcopenia, a condition characterized by loss of muscle mass, is a major concern, as it exacerbates morbidity and mortality.After transplantation, patients are at risk of developing neuromyopathy due to their hospitalization in intensive care. There is currently no effective preventive treatment for this condition, underlining the need for early rehabilitation strategies. The combination of sarcopenia and neuromyopathy diminishes their functional capabilities on discharge from the ICU.Muscle ultrasound, a simple, non-invasive technique, is already used to assess muscle function in intensive care patients. This study aims to evaluate the use of ultrasound to measure muscle loss in lung transplant patients, in particular by examining the rectus femoris muscle. Objectives include observing variations in the surface area of the rectus femoris muscle before and after transplantation, identifying factors influencing this variation, and exploring its relationship with post-transplant morbidity.In summary, this study seeks to better understand muscle loss in lung transplant patients using ultrasound, in order to identify risk factors and guide the development of post-transplant rehabilitation strategies., conditionsModule conditions: Lung Transplant, conditions: Physiotherapy, conditions: Sarcopenia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: ultrasound measurement of the cross-sectional area of the rectus femoris, outcomesModule primaryOutcomes measure: Evaluation of the change at D7 in the cross-sectional area of the rectus femoris following lung transplantation, secondaryOutcomes measure: Measure change in CSA-RF at D7 according to LT pattern, secondaryOutcomes measure: Evaluate the relationship between length of stay in intensive care unit and variation in CSA-RF at D7, secondaryOutcomes measure: Determine the relationship between CSA-RF at D-1 and Body Mass Index, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268158, orgStudyIdInfo id: 2023/45, briefTitle: The Effect of Eye Mask and Music on Sleep Quality and Delirium in Patients Monitored in Intensive Care Unit, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: TC Erciyes University, class: OTHER, descriptionModule briefSummary: After abdominal surgery, most patients experience problems such as respiratory complications, surgical wound infection, cardiac problems, renal failure, delirium, and insomnia, along with surgical trauma and underlying comorbidities. Postoperative delirium (POD) is an adverse postoperative complication that can occur in patients of all ages, from children to the elderly. Effective non-pharmacological treatment approaches for delirium include using an orientation board, calendar, clock, ensuring hydration, improving sleep quality, therapeutic activities, providing companionship of family members, and building private rooms. This study will be conducted as a randomized controlled and experimental study to determine the effect of eye patch and music on sleep quality and delirium in patients followed after abdominal surgery in the surgical intensive care unit.It was planned to include a total of 34 patients who underwent abdominal surgery, 17 in the experimental group and 17 in the control group.During the data collection phase, the Patient Information Form, Richard-Campbell Sleep Scale, Nursing Delirium Screening Scale and Richmond Agitation-Sedation Scale, will be used., conditionsModule conditions: Abdominal Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: Eye patch, outcomesModule primaryOutcomes measure: Richard-Campbell Sleep Scale, primaryOutcomes measure: Nursing Delirium Screening Scale, secondaryOutcomes measure: Richmond Agitation-Sedation Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erciyes University, status: RECRUITING, city: Kayseri, state: Talas, zip: 38080, country: Turkey, contacts name: Yeliz Sürme, PhD, role: CONTACT, phone: +0905532051130, email: yelizsurme@erciyes.edu.tr, contacts name: Tuğçe TOPAL, role: CONTACT, phone: +9005075698312, email: tugcetopal5@gmail.com, contacts name: Tuğçe TOPAL, Msn, role: PRINCIPAL_INVESTIGATOR, contacts name: Yeliz SÜRME, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.73222, lon: 35.48528, hasResults: False
protocolSection identificationModule nctId: NCT06268145, orgStudyIdInfo id: EC0006, briefTitle: ECC5004 RBA FE Study in Healthy Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-06, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-03-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Eccogene, class: INDUSTRY, descriptionModule briefSummary: This study is a Phase 1, open-label, randomized, single dose, fixed sequence, crossover study designed to compare the relative bioavailability of 50 mg ECC5004 current tablet formulation (F1) and 50 mg ECC5004 new tablet formulation (F2) under fasted and fed conditions in healthy participants, conditionsModule conditions: Type 2 Diabetes Mellitus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ESTIMATED, armsInterventionsModule interventions name: ECC5004, outcomesModule primaryOutcomes measure: ECC5004 PK parameters: AUC0-tlast, primaryOutcomes measure: ECC5004 PK parameters: AUC0-inf, primaryOutcomes measure: ECC5004 PK parameters: Cmax, primaryOutcomes measure: ECC5004 PK parameters: tmax, secondaryOutcomes measure: Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations, secondaryOutcomes measure: ECC5004 PK parameters: AUC0-tau, secondaryOutcomes measure: ECC5004 PK parameters: AUC 0-24, secondaryOutcomes measure: ECC5004 PK parameters: tlag, secondaryOutcomes measure: ECC5004 PK parameters: t1/2, secondaryOutcomes measure: ECC5004 PK parameters: CL/F, secondaryOutcomes measure: ECC5004 PK parameters: AUC(extr), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Eccogene Investigational Site, status: RECRUITING, city: Anaheim, state: California, zip: 92801, country: United States, contacts name: Eccogene, role: CONTACT, geoPoint lat: 33.83529, lon: -117.9145, hasResults: False